scholarly journals Case Report of Acquired Piritrexim Resistance and Collateral Methotrexate Sensitivity in Recurrent Squamous Cell Carcinoma of the Head and Neck

1993 ◽  
Vol 85 (15) ◽  
pp. 1248-1248 ◽  
Author(s):  
E. CVITKOVIC ◽  
C. DOMENGE ◽  
D. GANDIA
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Recurrent Squamous Cell Carcinoma

scholarly journals Papillary squamous cell carcinoma of the palatine tonsil: a rare cancer of the head and neck

2017 ◽  
Vol 37 (4) ◽  
pp. 341-345
Author(s):  
A. Serra ◽  
R. Caltabiano ◽  
G. Scalia ◽  
S. Palmucci ◽  
P. Di Mauro ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Palatine Tonsil ◽  
Rare Cancer ◽  
Hpv Dna ◽  
Papillary Squamous Cell Carcinoma

Le neoplasie squamose papillari delle vie aeree digestive superiori sono una rara variante del carcinoma a cellule squamose. Sono caratterizzate da una crescita esofitica papillare e hanno una prognosi generalmente favorevole. Il tumore è già stato descritto a livello delle vie aeree digestive superiori. In tale contesto, le localizzazioni più frequenti sono la laringe e l’ipofaringe, mentre raramente sono interessati la cavità orale e l’ipofaringe. Gli studi limitati unitamente all’esiguo numero di casi pubblicati di carcinoma squamoso papillare a localizzazione tonsillare, ci hanno indotto a una completa analisi di questo tumore, analizzando gli aspetti clinici, istopatologici, radiologici, virologici e terapeutici, non sempre presenti in letteratura. Un case report di carcinoma squamoso papillare della tonsilla palatina è pertanto riportato. La lesione (T2N0M0), localizzata a livello della tonsilla palatina sinistra, si aggettava verso la cavità orale. HPV DNA 16 e mRNA E6/E7 erano rilevati nella lesione. Un profilo della neoplasia è pertanto presentato unitamente a una completa revisione della recente letteratura, analizzando tutti gli aspetti di interesse di tale neoplasia.

scholarly journals Surgery for recurrent lower lip carcinoma

1970 ◽  
Vol 6 (3) ◽  
pp. 375-378
Author(s):  
S Maharjan ◽  
M Bista ◽  
KC Toran ◽  
KD Joshi
Keyword(s):  
Squamous Cell Carcinoma ◽  
Medical Journal ◽  
Case Report ◽  
Cell Carcinoma ◽  
Key Words ◽  
Squamous Cell ◽  
Lower Lip ◽  
Recurrent Squamous Cell Carcinoma ◽  
Lip Carcinoma ◽  
Deltopectoral Flap

A 38 year old gentleman presented with recurrent Squamos cell carcinoma of lower lip. He had earlier undergone previous surgeries and radiotherapy. At the time that he presented in KMCTH his lower lip area was much scarred and the tongue was shrunk and unavailable for vermilion reconstruction. This case report is an account of the various treatment carried out to reconstruct the lip. It was done with co-operation of the ENT department. Key words: Recurrent squamous cell carcinoma, Gillies fan flap, Deltopectoral flap, Delay of flaps doi: 10.3126/kumj.v6i3.1715 Kathmandu University Medical Journal (2008), Vol. 6, No. 3, Issue 23, 375-378

Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.

1986 ◽  
Vol 4 (11) ◽  
pp. 1670-1676 ◽  
Author(s):  
I W Dimery ◽  
S S Legha
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Hypertonic Saline ◽  
Squamous Cell ◽  
Renal Toxicity ◽  
Recurrent Squamous Cell Carcinoma ◽  
Duration Of Response ◽  
Median Cumulative Dose ◽  
To Receive

Fifty patients with histologically proven squamous-cell carcinoma of the head and neck, recurrent after surgery and/or radiation therapy, were treated with a triple-drug combination of methotrexate (MTX), 250 mg/m2 intravenously (IV) on day 1, followed by 5-fluorouracil (5-FU), 600 mg/m2 IV on days 1 and 2, followed by cisplatin, 50 to 60 mg/m2 IV on days 3 and 4. Patients were randomly assigned to receive cisplatin either in 300 mL of 3% saline or with standard mannitol diuresis along with appropriate hydration. The courses of treatment were repeated every 3 to 4 weeks. Among 47 evaluable patients, there were four complete responses (CRs) and 17 partial responses (PRs) (9% and 36%, respectively). The median duration of response was 23 weeks and the overall survival was 7 months. The median survival of responders v nonresponders was 12 months and 6 months, respectively. Nausea and vomiting was experienced by all patients and diarrhea was experienced by 36% of patients. Neutropenia occurred in 37 patients (79%) and resulted in fever or infection in 11 patients (23%) and death in two patients. Mild renal failure (persistent serum creatinine greater than 1.5 mg/ dL) was observed in ten patients (21%), six treated with 3% saline and four treated with mannitol. The median cumulative dose of cisplatin that lead to the development of renal impairment was 485 mg/m2 in the hypertonic saline arm and 550 mg/m2 in the mannitol arm (P = .40). The antitumor activity of this regimen was not superior to that of sequential MTX and 5-FU. The use of hypertonic saline was not effective in reducing the renal toxicity of cisplatin.

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

Oncology ◽  
2000 ◽  
Vol 60 (1) ◽  
pp. 66-71 ◽  
Author(s):  
X. Pivot ◽  
L. Cals ◽  
D. Cupissol ◽  
E. Guardiola ◽  
X. Tchiknavorian ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Squamous Cell ◽  
Phase Ii Trial ◽  
Recurrent Squamous Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document